Ads
related to: therapy notes pricing
Search results
OS Therapies Inc. Prices IPO at $4.00 Per Share (OSTX)
ETF DAILY NEWS· 2 days agoOS Therapies Inc. (OSTX) plans to raise $8 million in an initial public offering on Thursday, June 20th, IPO Scoop reports. The company will be issuing 2,000,000 shares at a price< ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 4 days agoFurther, Pfizer's gene therapy has been tied to safety issues. In this study, Pfizer says most...
uniQure director sells over $11k in company shares By Investing.com
Investing.com· 5 hours agoIt is important to note that this was not a discretionary trade by Mr. Kaye. Following the...
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst - Legend...
Benzinga· 12 hours agoShares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Missouri Independent via Yahoo News· 17 hours agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.1%
ETF DAILY NEWS· 2 days agoTaysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) traded down 4.1% on Friday . The company traded as low as $3.95 and last traded at $4.00. 191,240 shares were traded during trading ...
Piper Sandler keeps 'Overweight' on Allogene stock, highlights CAR-T potential By Investing.com
Investing.com· 14 hours agoOn Monday, Piper Sandler reaffirmed its Overweight rating on Allogene Therapeutics (NASDAQ:ALLO)...
Prison dance has 'profound' impact on dads and daughters
BBC via Yahoo News· 3 hours agoBut the dance itself is only part of the story. The event is preceded by a 10-week educational...
Syncona merges Freeline and SwanBio to spur new gene therapy-focused biotech
FierceBiotech· 13 hours agoSeven months after Syncona threw a financial lifeline to struggling Freeline Therapeutics, the...
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $550.00
ETF DAILY NEWS· 14 hours agoVertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by equities researchers at Argus from $465.00 to $550.00 in a note
Ad
related to: therapy notes pricing10.0/10 (1931 reviews)